Choice of Cost-Effectiveness Measure in the Economic Evaluation of Cholesterol-Modifying Pharmacotherapy: An Illustrative Example Focusing on the Primary Prevention of Coronary Heart Disease in Canada

By Morris S.  

PharmacoEconomics, Vol. 16, Iss. 2, 1999-08 ,pp. : 193-205

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis for Statin Therapies in the Primary Prevention of Coronary Heart Disease in Italy

By Berto P.  

Clinical Drug Investigation, Vol. 20, Iss. 2, 2000-08 ,pp. : 109-121

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Treatments to Reduce Cholesterol Levels, Blood Pressure and Smoking for the Prevention of Coronary Heart Disease: Evaluative Study Carried Out in Spain

By Plans-Rubió P.  

PharmacoEconomics, Vol. 13, Iss. 5, 1998-05 ,pp. : 623-643

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Coronary Heart Disease Prevention Strategies in Adults

By Brown A.D.  

PharmacoEconomics, Vol. 14, Iss. 1, 1998-07 ,pp. : 27-48

Adis International

Access to resources Recommend Favorite

Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness

By Ho Wai Khoon   Hankey Graeme J   Eikelboom John W  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 3, 2004-03 ,pp. : 493-503

Informa Healthcare

Access to resources Recommend Favorite